翰森制药(03692.HK)"盐酸厄洛替尼片"获药品注册批件
格隆汇6月4日丨翰森制药(03692.HK)宣布,由公司附属公司江苏豪森药业集团有限公司研发的"盐酸厄洛替尼片"已获得中华人民共和国国家药品监督管理局颁发药品注册批件。
该产品为抗肿瘤药物,适用于表皮生长因子受体(EGFR)基因具有敏感突变的局部晚期或转移性非小细胞肺癌(NSCLC)患者治疗,包括一线治疗、维持治疗,或既往接受过至少一次化疗进展后的二线及以上治疗。该产品获药品注册批件将进一步丰富和完善集团的肿瘤产品线布局。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.